#phase iii trial

1 story

#antibody-drug conjugate #cancer drug #cash runway #innate pharma #iph4502 #lacutamab #monalizumab #nasdaq ipha #q2 earnings #sezary syndrome #sobi

Innate Pharma Q2 Earnings Highlights
Innate Pharma secures $75m Sobi deal for cancer drug.
Yahoo Finance · 1m